Physician profile
Robert Kohn
NPI 1629082458
$3,706.91
in general payments reported to CMS, 2019-2025
16 companies · $992 in 2025
The $992 reported for 2025 was more than what 84% of Geriatric Psychiatry providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $144 · 2021: $314 · 2022: $591 · 2023: $719 · 2024: $556 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,983 · Consulting Fee: $200 · Education: $83.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,983.29 |
| Consulting Fee | $200.00 |
| Education | $83.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $934.07 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $634.98 | 2019-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $388.94 | 2021-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $361.56 | 2023-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Lundbeck LLC | $304.83 | 2021-2025 | Rexulti, Brintellix |
| Neurocrine Biosciences, INC. | $226.16 | 2022-2025 | Ingrezza |
| Janssen Scientific Affairs, LLC | $200.00 | 2025 | Spravato |
| Abbvie INC. | $182.13 | 2023-2025 | |
| Allergan, INC. | $135.31 | 2019 | |
| Eisai INC. | $100.25 | 2023 | |
| Merck Sharp & Dohme LLC | $75.01 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.79 | 2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.10 | 2022-2025 | Caplyta |
| Bausch Health US, LLC | $28.33 | 2022-2023 | Aplenzin |
| Alkermes, INC. | $26.33 | 2023 | Aristada, Lybalvi |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $21.12 | 2024 | Kisunla, Amyvid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.